Analysis of clinical manifestations and prognosis of primary systemic light chain amyloidosis with liver involvement
Objective: To summarize the clinical manifestations and prognostic factors of patients with hepatic amyloidosis in a single center. Methods: The clinical data of 28 primary systemic light chain amyloidosis cases with liver involvement in our center from October 2012 to January 2023 were retrospectively analyzed. The main clinical manifestations and prognostic factors were studied. Statistical analysis were performed using the χ(2) test, Fisher's exact test, Wilcoxon rank test, or Kaplan-Meier survival curve log-rank test according to the different data. Results: The main clinical manifestations of patients with liver involvement were abdominal distension, hepatomegaly, and edema. CD56 and chemokine receptor 4 protein expression accounted for 52% (13/25) and 56% (14/25). 64.3% (9/14) patients were combined with t (11,14), and 21.4% (3/14) patients were positive for 1q21 (+), and no patients were detected with del(17p). Univariate analysis showed that Mayo 2004 and 2012 stages and total bilirubin (TBil) ≥34.2 μmol/L were associated with progression-free survival and overall survival. The median progression-free survival and overall survival were significantly inferior in patients with TBil≥34.2μmol/L group (0.178 years, 0.195 years) than with the TBil<34.2μmol/L group (0.750 years, 3.586 years) (P < 0.05). Conclusion: Mayo stage and hyperbilirubinemia are inferior prognostic factors for patients with primary systemic light chain amyloidosis accompanied with liver involvement.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 32(2024), 3 vom: 20. März, Seite 222-227 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Qiao, T T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloidosis, liver |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn501113-20231108-00185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370735188 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370735188 | ||
| 003 | DE-627 | ||
| 005 | 20240409232835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn501113-20231108-00185 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM370735188 | ||
| 035 | |a (NLM)38584103 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Qiao, T T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of clinical manifestations and prognosis of primary systemic light chain amyloidosis with liver involvement |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: To summarize the clinical manifestations and prognostic factors of patients with hepatic amyloidosis in a single center. Methods: The clinical data of 28 primary systemic light chain amyloidosis cases with liver involvement in our center from October 2012 to January 2023 were retrospectively analyzed. The main clinical manifestations and prognostic factors were studied. Statistical analysis were performed using the χ(2) test, Fisher's exact test, Wilcoxon rank test, or Kaplan-Meier survival curve log-rank test according to the different data. Results: The main clinical manifestations of patients with liver involvement were abdominal distension, hepatomegaly, and edema. CD56 and chemokine receptor 4 protein expression accounted for 52% (13/25) and 56% (14/25). 64.3% (9/14) patients were combined with t (11,14), and 21.4% (3/14) patients were positive for 1q21 (+), and no patients were detected with del(17p). Univariate analysis showed that Mayo 2004 and 2012 stages and total bilirubin (TBil) ≥34.2 μmol/L were associated with progression-free survival and overall survival. The median progression-free survival and overall survival were significantly inferior in patients with TBil≥34.2μmol/L group (0.178 years, 0.195 years) than with the TBil<34.2μmol/L group (0.750 years, 3.586 years) (P < 0.05). Conclusion: Mayo stage and hyperbilirubinemia are inferior prognostic factors for patients with primary systemic light chain amyloidosis accompanied with liver involvement | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amyloidosis, liver | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Total bilirubin | |
| 700 | 1 | |a Liu, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, N |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, L Z |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, X L |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, L |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology |d 1998 |g 32(2024), 3 vom: 20. März, Seite 222-227 |w (DE-627)NLM096493321 |x 1007-3418 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:3 |g day:20 |g month:03 |g pages:222-227 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn501113-20231108-00185 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 3 |b 20 |c 03 |h 222-227 | ||